A closer look at “Bristol Myers Squibb CAR-T Trial Death Reported in Early Autoimmune Study”, exactly as the source publishes it. Bristol Myers Squibb has disclosed a patient death in an early-stage clinical trial of its investigational CAR-T therapy for autoimmune disease, raising safety concerns for the emerging class of cell therapies beyond oncology. The company confirmed the fatality but did not provide details on the cau The company confirmed the fatality but did not provide details on the cause or timing, according to a report by STAT News.
CAR-T therapies, which reengineer a patient's own immune cells to target disease, have shown promise in treating lupus and other autoimmune conditions, but this death underscores the potential risks of severe immune reactions and infections. The trial is one of several industry efforts to expand CAR-T into autoimmune disorders, a market that could be worth billions if proven safe and effective. This listing links straight to the original page, where the content is available in full.